{"id":"long-acting-beta-agonist","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"2-5","effect":"Nervousness/anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LABAs activate beta-2 adrenergic receptors, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation. This effect is sustained for 12-24 hours depending on the specific agent, making them suitable for maintenance therapy in chronic respiratory conditions. They are typically used in combination with inhaled corticosteroids to reduce exacerbations and improve lung function.","oneSentence":"Long-acting beta agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing prolonged relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:55.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT05935332","phase":"PHASE2","title":"Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2023-07-05","conditions":"Asthma","enrollment":38},{"nctId":"NCT05851443","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-11","conditions":"Moderate to Severe Asthma","enrollment":240},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07396311","phase":"","title":"Fractional Exhaled Nitric Oxide and Exacerbations of COPD","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":120},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT07198880","phase":"NA","title":"Impact of Home Non Invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Discharged From Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-01-01","conditions":"COPD, COPD (Chronic Obstructive Pulmonary Disease), Ventilation Therapy","enrollment":40},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":"Infertility, Female, Luteinizing Hormone (LH)","enrollment":590},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT06657066","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2021-12-06","conditions":"Asthma Patients","enrollment":74},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT00545844","phase":"PHASE4","title":"Singulair(R) In Asthma And Allergic Rhinitis (0476-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT05757908","phase":"NA","title":"Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist","status":"COMPLETED","sponsor":"Koneksa Health","startDate":"2023-04-21","conditions":"Moderate Asthma","enrollment":29},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT05078021","phase":"","title":"Phenotyping Disease Severity in Asthma","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-04-21","conditions":"Asthma","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT03527927","phase":"NA","title":"sTep dOWn Inhalers in the reAl woRlD","status":"COMPLETED","sponsor":"Hywel Dda Health Board","startDate":"2017-05-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":67},{"nctId":"NCT01108627","phase":"PHASE4","title":"Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists","status":"WITHDRAWN","sponsor":"Nemours Children's Clinic","startDate":"2010-10","conditions":"Safety of Long Acting Beta Agnoists","enrollment":""},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT04265105","phase":"PHASE2, PHASE3","title":"Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-12-22","conditions":"Asthma","enrollment":18},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03546907","phase":"PHASE2","title":"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-07-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":343},{"nctId":"NCT02232087","phase":"PHASE1","title":"Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2014-07","conditions":"Healthy","enrollment":52},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT04138758","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"COPD","enrollment":42953},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":"Physician's Practice Patterns","enrollment":236},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT03478657","phase":"PHASE4","title":"An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-18","conditions":"Asthma","enrollment":222},{"nctId":"NCT00448812","phase":"NA","title":"AIR Extension Study - Long-Term Safety of Alair Treated Subjects","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2005-03","conditions":"Asthma","enrollment":69},{"nctId":"NCT01185275","phase":"","title":"A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-08","conditions":"Asthma","enrollment":133},{"nctId":"NCT03964220","phase":"","title":"Impact of Tiotropium Add-on Therapy in Patients With Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-15","conditions":"Asthma","enrollment":7857},{"nctId":"NCT00749411","phase":"PHASE2","title":"Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":61},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT04456205","phase":"","title":"Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-01","conditions":"COPD, Inhaled Corticosteroid","enrollment":200},{"nctId":"NCT04322422","phase":"NA","title":"Clinical Characteristics and Treatment of Chest Tightness Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-06-01","conditions":"Asthma, Chest Syndrome, Clinical Anxiety","enrollment":300},{"nctId":"NCT02135692","phase":"PHASE3","title":"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-29","conditions":"Asthma","enrollment":339},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT04137029","phase":"NA","title":"Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, Pulmonology Scientific Research Institute","startDate":"2019-04-24","conditions":"Health, Subjective, Hyperreactivity, Bronchial","enrollment":20},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT00808288","phase":"PHASE2","title":"A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive","enrollment":405},{"nctId":"NCT01248208","phase":"PHASE1, PHASE2","title":"FluMist in Egg Allergic Patients","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"2010-09","conditions":"Egg Allergy, Eligible for Vaccination Against Influenza","enrollment":17},{"nctId":"NCT03655392","phase":"NA","title":"Clinical, Functional and Inflammatory Evaluation in Asthmatic Patients After a Simple Short-Term Educational Program","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-07-01","conditions":"Asthma, Inflammation, Patient Relations, Nurse","enrollment":64},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT01017952","phase":"PHASE3","title":"A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1635},{"nctId":"NCT01313650","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1538},{"nctId":"NCT01053988","phase":"PHASE3","title":"A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1031},{"nctId":"NCT01316887","phase":"PHASE3","title":"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":563},{"nctId":"NCT02014480","phase":"PHASE3","title":"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT01323621","phase":"PHASE3","title":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":512},{"nctId":"NCT01313637","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1493},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT01899742","phase":"PHASE3","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":497},{"nctId":"NCT01054885","phase":"PHASE3","title":"Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1226},{"nctId":"NCT01777334","phase":"PHASE3","title":"The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":905},{"nctId":"NCT01316900","phase":"PHASE3","title":"24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":846},{"nctId":"NCT00200967","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2004-12","conditions":"Asthma","enrollment":87},{"nctId":"NCT01072149","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT01009463","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1626},{"nctId":"NCT01336608","phase":"PHASE3","title":"A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":446},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01323634","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":519},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT01599871","phase":"PHASE3","title":"Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Hospital Son Espases","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":70},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT00964249","phase":"PHASE1","title":"Phase I Study of GW642444M in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":32},{"nctId":"NCT00783003","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT02953041","phase":"PHASE4","title":"Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2016-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT00595361","phase":"NA","title":"How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01437995","phase":"PHASE4","title":"Long-acting Beta Agonist Step Down Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Asthma","enrollment":459},{"nctId":"NCT01443845","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-30","conditions":"COPD, COPD Exacerbation, Lung Diseases","enrollment":2354},{"nctId":"NCT01316913","phase":"PHASE3","title":"24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":872},{"nctId":"NCT01772147","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":608},{"nctId":"NCT01376245","phase":"PHASE3","title":"A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":646},{"nctId":"NCT01716520","phase":"PHASE3","title":"Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":182},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT00910689","phase":"PHASE4","title":"Drug and Non-Drug Treatment Of Severe Migraine","status":"COMPLETED","sponsor":"Ohio University","startDate":"2001-07","conditions":"Migraine Headache","enrollment":232},{"nctId":"NCT01948401","phase":"PHASE2","title":"A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07","conditions":"Asthma","enrollment":54},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT01712854","phase":"PHASE4","title":"Effects of Symbicort on the Ventilatory Kinematics","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-03","conditions":"Chronic Obstructive Lung Disease","enrollment":9},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT02850484","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2016-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":99},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"MEDICATION ERROR"},{"count":1,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":1,"reaction":"TREATMENT FAILURE"},{"count":1,"reaction":"VENTRICULAR TACHYCARDIA"}],"_approvalHistory":[],"publicationCount":703,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Serevent","Oxeze"],"phase":"marketed","status":"active","brandName":"long acting beta agonist","genericName":"long acting beta agonist","companyName":"University of Alberta","companyId":"university-of-alberta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting beta agonists are small molecule medications used to treat conditions such as asthma, chest syndrome, and lung function issues. They are often administered in combination with inhaled corticosteroids and may be used to treat other conditions including clinical anxiety and depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}